Pedro Cahn1, Richard Kaplan2, Paul E Sax3, Kathleen Squires4, Jean-Michel Molina5, Anchalee Avihingsanon6, Winai Ratanasuwan7, Evelyn Rojas8, Mohammed Rassool9, Mark Bloch10, Linos Vandekerckhove11, Peter Ruane12, Yazdan Yazdanpanah13, Christine Katlama14, Xia Xu15, Anthony Rodgers15, Lilly East15, Larissa Wenning15, Sandy Rawlins15, Brenda Homony15, Peter Sklar15, Bach-Yen Nguyen15, Randi Leavitt15, Hedy Teppler16. 1. Fundación Huesped, Buenos Aires, Argentina. 2. Desmond Tutu HIV Foundation, Cape Town, South Africa. 3. Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA. 4. Thomas Jefferson University, Philadelphia, PA, USA. 5. Department of Infectious Diseases, Saint-Louis Hospital, APHP, University of Paris, Paris, France. 6. HIV-NAT, Thai Red Cross AIDS Research Center and Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. 7. Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. 8. Cericap Multiclinicas, Edifico Galerías, Guatemala City, Guatemala. 9. University of Witwatersrand, Helen Joseph Hospital, Johannesburg, South Africa. 10. Holdsworth House Medical Practice, Sydney NSW, Australia. 11. Faculty of Medicine and Health Sciences, University of Ghent, Ghent, Belgium. 12. Ruane Medical & Liver Health Institute, Los Angeles, CA, USA. 13. Hôpital Bichat-Claude Bernard, Paris, France. 14. Hôpital Pitié-Salpêtrière Pavillon Laveran, Paris, France. 15. Merck & Co, Inc, Kenilworth, NJ, USA. 16. Merck & Co, Inc, Kenilworth, NJ, USA. Electronic address: hedy_teppler@merck.com.
Abstract
BACKGROUND: Once daily regimens are preferred for HIV-1 treatment, to facilitate adherence and improve quality of life. We compared a new once daily formulation of raltegravir to the currently marketed twice daily formulation. METHODS: In this randomised, double-blind, parallel-group, phase 3, non-inferiority study, we enrolled participants aged 18 years or older with HIV-1 RNA of 1000 or more copies per mL and no previous antiretroviral treatment at 139 sites worldwide. We randomly assigned participants (2:1) via an interactive voice and web response system to raltegravir 1200 mg (two 600 mg tablets) orally once daily or raltegravir 400 mg (one tablet) orally twice daily, each with tenofovir disoproxil fumarate and emtricitabine orally once daily, for up to 96 weeks. A computer-generated allocation schedule stratified randomisation by screening HIV-1 RNA value and co-infection with hepatitis B or C. Participants, sponsor personnel, investigators, and study site personnel involved in the treatment or evaluation of the participants were unaware of the treatment group assignments. The primary endpoint was the proportion of participants with HIV-1 RNA less than 40 copies per mL at week 48 assessed with the US Food and Drug Administration Snapshot algorithm. Non-inferiority was concluded if the lower bound of the two-sided 95% CI was greater than -10%. We assessed efficacy and safety in all participants who received one dose or more of study treatment. This study is registered with ClinicalTrials.gov, number NCT02131233. FINDINGS:Between May 26, 2014, and Dec 5, 2014, 802 participants were enrolled and randomly assigned, 533 to once daily treatment and 269 to twice daily; 797 received study therapy, 531 once daily and 266 twice daily. At week 48, 472 (89%) of 531 once daily recipients and 235 (88%) of 266 twice daily recipients achieved HIV-1 RNA less than 40 copies per mL (treatment difference 0·5%, 95% CI -4·2 to 5·2). Drug-related adverse events occurred in 130 (24%) of 531 participants in the once daily group (one of which was serious; none led to treatment discontinuation) and 68 (26%) of 266 participants in the twice daily group (two of which were serious; two led to treatment discontinuation). The most common drug-related adverse events were nausea (39 [7%] vs 18 [7%]), headache (16 [3%] vs 12 [5%]), and dizziness (12 [2%] vs eight [3%]). No treatment-related deaths were reported. INTERPRETATION: A once daily raltegravir 1200 mg regimen was non-inferior compared with raltegravir 400 mg twice daily for initial treatment of HIV-1 infection. These results support the use of raltegravir 1200 mg once daily for first-line therapy. FUNDING: Merck & Co, Inc.
RCT Entities:
BACKGROUND: Once daily regimens are preferred for HIV-1 treatment, to facilitate adherence and improve quality of life. We compared a new once daily formulation of raltegravir to the currently marketed twice daily formulation. METHODS: In this randomised, double-blind, parallel-group, phase 3, non-inferiority study, we enrolled participants aged 18 years or older with HIV-1 RNA of 1000 or more copies per mL and no previous antiretroviral treatment at 139 sites worldwide. We randomly assigned participants (2:1) via an interactive voice and web response system to raltegravir 1200 mg (two 600 mg tablets) orally once daily or raltegravir 400 mg (one tablet) orally twice daily, each with tenofovir disoproxil fumarate and emtricitabine orally once daily, for up to 96 weeks. A computer-generated allocation schedule stratified randomisation by screening HIV-1 RNA value and co-infection with hepatitis B or C. Participants, sponsor personnel, investigators, and study site personnel involved in the treatment or evaluation of the participants were unaware of the treatment group assignments. The primary endpoint was the proportion of participants with HIV-1 RNA less than 40 copies per mL at week 48 assessed with the US Food and Drug Administration Snapshot algorithm. Non-inferiority was concluded if the lower bound of the two-sided 95% CI was greater than -10%. We assessed efficacy and safety in all participants who received one dose or more of study treatment. This study is registered with ClinicalTrials.gov, number NCT02131233. FINDINGS: Between May 26, 2014, and Dec 5, 2014, 802 participants were enrolled and randomly assigned, 533 to once daily treatment and 269 to twice daily; 797 received study therapy, 531 once daily and 266 twice daily. At week 48, 472 (89%) of 531 once daily recipients and 235 (88%) of 266 twice daily recipients achieved HIV-1 RNA less than 40 copies per mL (treatment difference 0·5%, 95% CI -4·2 to 5·2). Drug-related adverse events occurred in 130 (24%) of 531 participants in the once daily group (one of which was serious; none led to treatment discontinuation) and 68 (26%) of 266 participants in the twice daily group (two of which were serious; two led to treatment discontinuation). The most common drug-related adverse events were nausea (39 [7%] vs 18 [7%]), headache (16 [3%] vs 12 [5%]), and dizziness (12 [2%] vs eight [3%]). No treatment-related deaths were reported. INTERPRETATION: A once daily raltegravir 1200 mg regimen was non-inferior compared with raltegravir 400 mg twice daily for initial treatment of HIV-1 infection. These results support the use of raltegravir 1200 mg once daily for first-line therapy. FUNDING: Merck & Co, Inc.
Authors: Rohan Gurjar; Laura Dickinson; Daniel Carr; Wolfgang Stöhr; Stefano Bonora; Andrew Owen; Antonio D'Avolio; Adam Cursley; Nathalie De Castro; Gerd Fätkenheuer; Linos Vandekerckhove; Giovanni Di Perri; Anton Pozniak; Christine Schwimmer; François Raffi; Marta Boffito Journal: Pharmacogenomics J Date: 2022-10-20 Impact factor: 3.245
Authors: Kimberly K Scarsi; Joshua P Havens; Anthony T Podany; Sean N Avedissian; Courtney V Fletcher Journal: Drugs Date: 2020-11 Impact factor: 9.546
Authors: Jesús Troya; Rocio Montejano; Pablo Ryan; Cristina Gómez; Mariano Matarranz; Alfonso Cabello; Francisco Vera; María Antonia Sepúlveda; Ignacio Santos; Gloria Samperiz; Pablo Bachiller; Vicente Boix; Pilar Barrufet; Miguel Cervero; José Sanz; Javier Solís; María Yllescas; Eulalia Valencia Journal: PLoS One Date: 2018-06-14 Impact factor: 3.240
Authors: Pedro Cahn; Paul E Sax; Kathleen Squires; Jean-Michel Molina; Winai Ratanasuwan; Mohammed Rassool; Mark Bloch; Xia Xu; Yan Zhou; Brenda Homony; Deborah Hepler; Hedy Teppler; George J Hanna; Bach-Yen Nguyen; Wayne Greaves Journal: J Acquir Immune Defic Syndr Date: 2018-08-15 Impact factor: 3.731